CooperSurgical Inc.

Management explained that after talking to several interested buyers, several factors influenced valuation, and late in the process, that valuation started to come down.

The result, according to management, quote, "A temporary disconnect between Cooper Surgical's intrinsic value and offers received, resulting in proposals that did not adequately reflect the full value and long-term potential of the business." Hannah, this seems like management speak for we could not get the price we wanted.

Yeah, 100%.

And I think that's, that's what makes this so frustrating for investors.

This paper is entitled Segmental Anteploid in Human Embryos is Frequently Mosaic with Evidence of Meiotic Origin, Insights from Trophectoderm and Inner Cell Mass Analysis.

This paper comes to us from across the pond by first author Al Hashimi, as well as some friends of the pod, Nick Macklin, Tony Gordon, and Darren Griffin, coming to us from London Women's Clinic Institute for Women's Health at University College London, as well with contributions by Cooper Surgical.

So let's talk about segmental aneuploidy for a second.

Segmental aneuploidy appears in about 7% to 15% of biopsy blastocysts and is functionally the more confusing line of the PGTA report.

They had the initial clinical biopsy taken at the time of the actual embryo creation.

Then they thawed these embryos, collected a second trophectoderm biopsy, and then they also had the entire inner cell mass that was available, micro-dissected, and able to be analyzed.

Analysis was performed on the PGT-Complete platform, which is a Cooper Surgical product.

They did the low-pass whole genome sequencing, but they also had integrated SNP analysis that along with parental buccal swabs that allowed to assess the origin of some of these abnormalities in embryos.